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The structure of the dynorphin (1–13) peptide (dynorphin) bound to
the human kappa opioid receptor (KOR) has been determined by
liquid-state NMR spectroscopy. 1H and 15N chemical shift variations
indicated that free and bound peptide is in fast exchange in solu-
tions containing 1 mM dynorphin and 0.01 mM KOR. Radioligand
binding indicated an intermediate-affinity interaction, with a Kd of
∼200 nM. Transferred nuclear Overhauser enhancement spectros-
copy was used to determine the structure of bound dynorphin. The
N-terminal opioid signature, YGGF, was observed to be flexibly dis-
ordered, the central part of the peptide from L5 to R9 to form a he-
lical turn, and the C-terminal segment from P10 to K13 to be flexibly
disordered in this intermediate-affinity bound state. Combining mo-
lecular modeling with NMR provided an initial framework for under-
standing multistep activation of a G protein-coupled receptor by its
cognate peptide ligand.
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Gprotein-coupled receptors (GPCRs) are the largest super-family of membrane proteins in the human genome and play
a critical role in human physiology by initiating signal transduc-
tion in response to extracellular stimuli (1, 2). Since 2007, 89
GPCR crystal structures have been reported, including receptors
in inactive and active states, as well as the beta-2 adrenergic
receptor (β2-AR) bound to heterotrimeric G proteins (3). NMR
spectroscopy has revealed that the intrinsic conformational
heterogeneity of GPCRs is influenced by ligand pharmacology,
membrane composition, and effector interactions (4–6). These
structural biology studies have provided atomic-resolution insights
of systems defined by dynamic structural rearrangements that are
correlated with diverse cellular and physiological outcomes.
The classic opioid receptors (δ/κ/μ) are GPCRs activated in
response to binding enkephalin-like peptide agonists and are the
primary targets of widely prescribed pain medications (7). The
kappa opioid receptor (KOR) and its cognate peptide dynorphin
are implicated in neuronal pathways associated with addiction,
pain, reward, mood, cognition, and perception (8, 9). Nonselective
KOR antagonists such as naltrexone have been prescribed for al-
cohol dependence with limited efficacy in humans, and next-gen-
eration KOR antagonists continue to be developed to treat drug
addiction and other disorders. Although much is known regarding
the antagonist-bound, inactive state of GPCRs, including the crys-
tal structure of JDTic-bound KOR, the interaction of these re-
ceptors with neuropeptide agonists remains largely unknown (10).
Peptide agonist-bound structures have thus far been limited to a
conformationally stabilized neurotensin receptor, likely corre-
sponding to a low-energy peptide-receptor state (11–13).
Dynorphin was discovered by Goldstein and Chavkin as the
endogenous activating neuropeptide for KOR, with a “low-reso-
lution” structural model of interaction proposed to PNAS in 1981
(14, 15). Dynorphins are derived from the precursor prodynorphin,
with dynorphin A(1–17), dynorphin B(1–13), and alpha neoen-
dorphin sharing a highly conserved N-terminal sequence and
charge distribution (16). Dynorphin A(1–13) was shown to act as
an agonist on opioid kappa receptors in vivo (17). Physiological
activation of KOR is mainly associated with unwanted effects
such as dysphoria, anhedonia, and hallucinations, and a current
hypothesis in the field is that KOR functionally selective ligands
may produce analgesia without dysphoria (18, 19). Functional
selectivity has emerged as the leading model to understand the
ability of a ligand to activate a subset of signaling cascades,
providing a framework for developing next-generation drugs with
rationally designed pharmacological profiles (20).
The seminal work of Schwyzer in the 1970s and 1980s led to a
model of KOR activation by dynorphin that proceeds via a multi-
step binding mechanism (14, 21, 22). Thereby, low- to intermediate-
affinity binding states of dynorphin correspond to binding to cell-
surface membranes or to extracellular loops of the GPCR. A
“message–address” paradigm has been formulated based on
structure–activity relations observed with dynorphin analogs (21–
26). Accordingly, the N-terminal YGGF “message” sequence,
which is common to all opioid peptides, was found to be re-
sponsible for receptor activation. A C-terminal “address” sequence
was further found to contribute via electrostatically driven in-
teractions to KOR subtype specificity. In the context of this para-
digm, the present study yields intriguing data on the N-terminal
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segment of the KOR-bound opioid peptide dynorphin. The meth-
ods used, NMR in solution and molecular dynamics simulations,
enabled us to define structural ensembles of KOR-bound dynorphin
and to characterize internal peptide motions in the presently pre-
pared low-affinity receptor-bound state.
Results
We prepared KOR with the approach used to solve the crystal
structure in complex with JDTic by X-ray crystallography (10). The
membrane fraction of Spodoptera frugiperda cells transiently ex-
pressing KOR was isolated and radioligand binding assays per-
formed to assess receptor function. Dynorphin binding affinity was
determined as ∼200 nM at pH 7.4 and 6.1, consistent with an in-
termediate-affinity interaction (Fig. S1A). Following reconstitution
of the receptor in detergent micelles and purification to >95%
homogeneity, similar binding was measured and the preparation
was stable at 7 °C for over a week (Fig. S1B). The following ob-
servations, made in the absence of G protein, thus characterize an
intermediate state of KOR along its activation pathway, similar to
what was recently described by 13C-NMR for β2-AR (27).
The dynorphin (1–13) peptide, YGGFLRRIRPKLK, was
15N-labeled at residues G2, G3, F4, L5, R6, R7, I8, R9, and L12.
[15N, 1H]-heteronuclear single quantum correlation (HSQC) NMR
spectra of 15N-(GFLIR)-dynorphin at pH 6.1 and pH 7.4 indicated
the peptide adopts a random coil conformation in aqueous solution.
Owing to little dependence of binding on pH, measurements were
made at pH 6.1 to reduce proton exchange with solvent. Resonance
assignments were obtained with 2D [1H, 1H]-total correlation spec-
troscopy (TOCSY) and nuclear Overhauser effect spectros-
copy (NOESY), 2D [15N, 1H]-HSQC, [13C, 1H]-HSQC, and 3D
CBCANH experiments, using standard pulse sequences and a
classical 1H assignment strategy for small peptides (28). 1H, 13C, and
15N resonance assignments were deposited to the Biological Mag-
netic Resonance Data Bank (BMRB; accession no. 25597) (29).
Detergent-reconstituted KOR was added to an aqueous solu-
tion of dynorphin at a ratio of 1:100, with a 1 mM final concen-
tration of peptide. KOR-specific binding of dynorphin was
reversed by the addition of the high-affinity ligand JDTic at a
molar ratio of 1:1 with respect to dynorphin. We thus isolated by
difference analysis the nonspecific binding of dynorphin to the
mixed detergent-sterol micelle of dodecyl maltoside/cholesteryl
hemisuccinate (DDM/CHS). NMR-derived values such as chemical
shift, NOE intensity, and relaxation rate constants (R1, R2, and
1H-15N NOEs) were obtained with and without JDTic to charac-
terize a KOR-bound conformation of dynorphin.
Chemical Shift Perturbations. KOR-binding produced distinct pat-
terns of dynorphin 1H, 15N, and 13C chemical shift changes detected
in 1D proton and 2D heteronuclear correlation NMR experiments,
as shown in Fig. 1. The observation of chemical shift changes shows
that the exchange rate between KOR-bound and KOR-unbound
states is fast on the millisecond time scale, as the frequency dif-
ference between bound and unbound state is on the order of 103
Hz (Fig. 1C; see Supporting Information for further considerations
on exchange rates). The sequence-specific changes were largest
from L5 to R9, with smaller changes observed from G2 to F4
and K11 to K13. 15N-1H correlation experiments acquired without
proton decoupling in the in-phase/anti-phase method (HSQC-
IPAP) were obtained to determine 1JNH (30). No significant vari-
ations on the 15N-1H couplings was observed in HSQC-IPAP ex-
periments, consistent with negligible residual dipolar couplings,
and therefore anisotropic interactions do not contribute to the
observed phenomena. The shifts observed on 1H and 15N are too
large to be accounted for by secondary structure alone and likely
reflect a ring current effect due to the receptor proximity. We
measured the 13C chemical shifts of C′, Cα, and Cβ of 13C-labeled
arginine residues (R6, R7, and R9), because these values report on
secondary structure (31). Based on carbon chemical shifts, a helical
conformation was expected for R6 and R7, in contrast to R9. In
addition to JDTic competition, the inhibition of dynorphin-specific
binding was also observed using the highly potent KOR agonist
ICI-199,441 (32). The observations and analysis performed here
therefore describe a property of KOR–dynorphin-specific in-
teraction reversible by agonists and antagonists.
Nuclear Overhauser Effects and Structure Determination. Where li-
gand exchange between a bound and free state is considered fast
(koff > R1), transferred NOEs (trNOEs) originating from the
receptor-bound state may be observed on the free peptide
spectrum. The measured 1H R1 values for amide protons in the
free state depended on the residue and ranged from 1.2 to 1.8 s−1
(Fig. S2). As expected from simulations (Fig. S3), our mea-
surements confirm the dominant contribution of unbound









































































Fig. 1. Influence of KOR and JDTic on NMR spectra of dynorphin. (A) (top, black) 1D 1H-NMR expansion of the NH region of dynorphin in aqueous solution at pH 6.1
acquired at 280 K. (middle, red) Addition of DDM/CHS reconstituted KOR induces significant line broadening for all resonances. The least broadened resonances were K11,
L12, and K13. (bottom, blue) The addition of JDTic largely reversed the observed broadening and chemical shift changes, particularly for residues F4 to R9. (B) Overlay of
two [15N, 1H]-HSQC-IPAP spectra: (red) KOR + dynorphin and (blue) KOR + dynorphin + JDTic. L5 chemical shift perturbations are mainly in the 15N dimension whereas I8
changes were observed in both 1H and 15N dimensions. The complete spectrum is available in Fig. S4. (C) Chemical shift perturbations of dynorphin as a result of KOR
binding, calculated as the difference of chemical shifts of dynorphin with KOR and KOR + JDTic. Gray bars (left axis): 1H chemical shifts; white bars (right axis): 15N chemical
shifts. The [KOR]/[dynorphin] ratio was 1/100. Almost no chemical shift variations were observed for the C-terminal tripeptide segment.
























the weighted average between the bound and free state contri-
butions (33). The σij range from 100 to 600 Hz in the bound state
and from 0.5 to 3 Hz in the free state and are thus lower than koff
for dynorphin–KOR exchange in our experimental conditions.
[1H, 1H]-NOESY experiments recorded in the presence and
absence of JDTic revealed distinct cross-peak distributions (Fig.
2A). NOE build-up curves were obtained from NOESY experi-
ments at four mixing times: 50, 100, 200, and 500 ms. Fig. 2B
shows a characteristic long-range NOE between the G3α and R6
amide protons. For many resonances, a significant qualitative
difference was observed for the build-up rate of NOE intensities
with and without JDTic.
The observed NOE build-up differences were thus converted
into NMR-derived structural distance restraints using a biexpo-
nential fitting routine. Fifty-six significant restraints were used for
structure determination (Table 1). Fig. 2C qualitatively shows the
most significant restraints. Medium- and long-range restraints are
clearly concentrated in the central part of the peptide, from F4 to
R9. The distance restraints and the R6–R7 dihedral angle re-
straints were used to determine the structure of dynorphin bound
to KOR using a restrained molecular dynamics (MD) protocol as
described in Materials and Methods and Supporting Information.
The structure of KOR-bound dynorphin is shown in Fig. 2D as an
ensemble of 10 best-fit structures derived from the structure de-
termination protocol. In agreement with the restraint table, we
found that the central part (from L5 to R9) of the peptide forms a
well-defined α-helical turn whereas the N- and C-terminal por-
tions, Y1–F4 and P10–K13, are flexibly disordered.
15N Relaxation Times. Measurement of 15N relaxation rates are
routinely applied in protein NMR to characterize internal dy-
namics. We determined 15N T1, T2, and
1H-15N heteronuclear
NOEs (hetNOEs) on a peptide 15N-labeled on GFLI residues to
assess the peptide dynamics (Fig. S2). Significant variation of the
15N relaxation parameters was observed exclusively for T2 re-
laxation times, and thus the related relaxation rate constant R2.
The exclusive variation of R2 correlates with fast
15N-dynorphin
exchange between free and bound states, with a KOR-bound
correlation time (τc) of 10−7 to 10−6 s, whereas nonspecifically
bound peptide has a shorter τc of 10−9 to 10−8 s (Fig. S3). 15N T1
and 15N-1H hetNOEs do not contain significant information on
the KOR-bound state (Materials and Methods and Figs. S2 and
S3). Following these observations, a second set of 15N T2 re-
laxation measurements were made on 15N-(GFLI)-,15N,13C-(R)-
dynorphin, as shown in Fig. 3A.
The difference in R2 due to KOR binding was recognized as
directly proportional to the order parameter, S2, which describes
the amplitude of internal motion of the NH vector (Fig. 3B).
Changes to R2 were greater for residues L5–R9 than for G2–F4,
and L12 was least affected. In the KOR-bound state, the NH bonds
of L5 to R9 are clearly more immobilized than the N and C ter-
mini. The 1H-NMR spectrum also indicates the resonances of K11,
L12, and K13 were not as broadened by chemical exchange, con-
firming that these last three residues remain mobile. The internal
dynamics of dynorphin are therefore consistent with measured
chemical shift perturbations, NOE patterns, and structure in terms
of sequence-specific changes. Collectively, these NMR measure-
ments of 15N-dynorphin reflect significant residual mobility in the
KOR-bound conformation studied here.
Quantitative analysis of intraresidual NOEs was performed for
the side chains of Y1, F4, and P10 where interatomic distances are
known. From the initial build-up rates of trNOEs we derived order
parameters and found S2 for F4 was approximately twice that of
Y1, and fourfold greater than that of P10. The mobility profile
obtained from 15N measurements was thus extended, revealing the
phenolic ring of Y1 remains mobile in a KOR-bound state. In-
terestingly, the F4 aromatic ring is more immobilized than the
F4 NH vector (Fig. 3B). Similarly, the R9 NH vector has a high S2
value, whereas the R9 13C chemical shift indicated the helix is
interrupted at the R9 dihedral angles. From the rmsd of the
structure determination (Table 1), the helix is defined from L5 to
I8, and extends slightly toward F4 (but not its NH) and toward R9
NH (but not its Cα or C′ atoms).
Molecular Modeling of KOR–Dynorphin. Starting from the opioid re-
ceptor structures 4DJH (KOR), 4N6H (DOR), and 4DKL (MOR),
we generated an ensemble of six structures representative of the
opioid receptor binding pocket. Flexible docking of dynorphin was
performed with a rigid helical turn and MD simulations performed
with explicit water (Fig. S5). Five major dynorphin conformations
were identified, revealing significant structural diversity in both N and
C termini (Table S1; the corresponding pdb files of the peptide re-
ceptor complexes are available in Datasets S1–S5). Averaging of NH
orientations over five MD simulations, starting from these five poses,
in equal proportion, was required to reproduce experimental data.
A comparison of opioid receptor crystal structures provided the
basis for interpreting the results from MD. We observed that the

















































Fig. 2. Structure determination of a KOR-bound conformation of dynorphin.
(A) Overlay of two 2D [1H, 1H]-NOESY spectra: (red) KOR + dynorphin and (blue)
KOR + dynorphin + JDTic; 800 MHz, 100-ms mixing time, 280 K. (B) NOE build-
up curves for dynorphin cross-peak G3 Hα–R6 HN in the presence of (red) KOR
and (blue) KOR + JDTic. (C) Summary of the most significant NOEs defining the
secondary structure. These NOEs are the difference between the observed NOEs
in the absence and in the presence of JDTic and are thus representative of KOR
specific binding. Note the absence of medium-range NOEs in the N and C
termini. (D) Conformational ensemble of 10 structures of dynorphin bound to
KOR after restrained MD protocols, using the constraints given in Table 1.
Table 1. Statistics for the KOR-bound dynorphin structure
determination
No. of restraints for calculations
Sequential 42
Medium-range (n to n + 2,3,4) 14
Dihedral angles 4
Restraint violations
NOE restraints, Å 0.07
Coordinate precision: rmsd of backbone atoms, Å
Residues 1–4 1.76 ± 0.53
Residues 5–8 0.46 ± 0.16
Residues 9–13 5.47 ± 1.92
Residues 1–13 3.57 ± 1.11
Rmsds were computed on the bundle of 10 best conformers used to
represent the KOR-bound structure of dynorphin (1–13) (Fig. 2D). More de-
tailed statistics and structure validation parameters can be found in Table S2.
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terms of position in the orthosteric site, for antagonist-bound
structures of KOR-JDTic, DOR-DIPP, and MOR-funaltrexamine
(Fig. 4A). Following MD simulations the “KOR-1” structural
model revealed Y1 in a position near the phenol-piperidine fused-
ring system of JDTic, resembling a previously proposed pose (Fig.
4B) (9). The “KOR-2” pose of dynorphin placed the Y1 side chain
in the sodium allosteric site (Fig. 4C). D3.32 made polar contacts
with Y1, G2, and G3 in both KOR-1 and KOR-2 models, whereas
R7 made a polar contact in KOR-2 but not KOR-1. W6.48 and
N7.45 made contacts with Y1 in the KOR-2 model exclusively.
Table 2 and Table S1 summarize the findings from modeling and
MD simulations, with further details given in Materials and Meth-
ods and Supporting Information.
Discussion
Since the 1970s, pharmacologists and biochemists have attempted
to determine opioid peptide conformations capable of explaining
their activity and to develop drugs mimicking these conformations
(34). In aqueous solutions, peptides often exist as a dynamic en-
semble of random coil conformers, with specific folds stabilized by
organic solvents or micelles (35–37). Studies of liposome-bound
peptides likewise indicate that nonpolar or membrane-like envi-
ronments stabilize peptide structure (23, 24, 38–41). Schwyzer in-
troduced the “membrane compartment concept” that postulated
the membrane-bound state as part of the binding mechanism,
thereby reducing the available peptide conformations toward an
activating conformation in complex with receptor (21, 22, 25). For
many years, the direct analysis of the peptide–receptor complex
was not possible due to the lack of suitable receptor preparations.
Recently, several neurotensin–receptor complexes have been stud-
ied both by X-ray crystallography and solid-state NMR (11–13),
and the structure of the Leukotriene B4 (a proinflammatory lipid
mediator), in complex with the human BLT2 receptor, was de-
termined by liquid-state NMR (41).
Recent advances in producing the opioid receptors (and other
GPCRs) in milligram quantities via transient insect cell expression
and stabilization in a bicelle-like architecture of mixed detergent-
sterol micelles has opened new avenues for opioid receptor
structural biology (42). This progress culminated in 2012, with re-
ports of inactive state structures determined by X-ray crystallogra-
phy of the four opioid receptors in complex with antagonists or
inverse agonists (10, 43–46). Currently, the only reported 3D
structure of the human KOR is in complex with JDTic, a highly
potent KOR antagonist.
NMR using (15N-13C)–labeled ligand represents a powerful com-
plementary alternative to crystallographic approaches in obtaining
structural information of receptor activation by peptide agonists.
Owing to the moderate affinity of dynorphin with KOR recon-
stituted in detergent micelles and fast association rate, the ligand
dissociation rate is also fast on the NMR chemical shift time
scale (47). This context made possible the observation of trNOEs
and a straightforward interpretation of 15N relaxation rates (33).
The receptor–peptide interaction was therefore ideal to determine
a KOR-bound conformation of dynorphin via the trNOE method,
as well as to characterize internal peptide dynamics in a bound
state. Such an approach would be prohibited in a comparable
study of the high-affinity state, which is characterized by low
nanomolar Kd and longer off-rate. In this case, changes to
dynorphin structure and dynamics are expected as a result of G
protein binding to KOR. Nevertheless, NMR observation of the
high-affinity state of dynorphin can be pursued by deuteration of
the receptor, peptide, and cognate inhibitory G proteins and
preparation of a 1:1:1 complex at millimolar concentrations.
The computational approaches were insufficient to determine
reasonable models of dynorphin–KOR binding, because multiple
conformers of similar energy were observed. The NMR observa-
tions of structure and dynamics were required to limit the starting
poses of dynorphin for MD. We identified the pose KOR-1 as
typical of an inactive state based on the proximity of Y1 to the
phenol-like functional group of JDTic (Fig. 4B and Fig. S6B). In
contrast, we speculate the conformational change of the peptide
found in KOR-2 correlates with an activated state (Fig. 4 B and C
and Fig. S6D). The position of Y1 in the KOR-2 model corresponds
with an established role in activation, with the dynorphin (2–13)
peptide previously reported to bind weakly and not activate KOR
(48). In this “active” conformation, the N terminus of dynorphin
forms polar interactions with N3.35 and D3.32 side chains, whereas
the Y1 phenol ring is involved in a π-stacking interaction with W6.48
and an H-bond with N7.45. As part of the allosteric sodium site these
residues stabilize an inactive state of the receptor, with changes to
dynorphin structure providing agonist–receptor contacts among
highly conserved residues in transmembrane helices 6 and 7 (43).
Interestingly, this conformational change may be associated with an
A B
C D
Fig. 4. Ligand poses from modeling the dynorphin–KOR complex. (A) Antag-
onist binding poses from structures of KOR-JDTic (4DJH), DOR-DIPP (4RWA), and
MOR-FNA (4DKL). JDTic is shown in green, DIPP in purple, and β-funaltrexamine
in salmon. (B) Structure of dynorphin in complex with “KOR-1” from MD simu-
lations with Y1 in a position near the fused phenol-piperidine ring system of
JDTic. (C) Zoom on dynorphin Y1 in the “KOR-2” complex. Y1 is positioned to-
ward the sodium allosteric binding site. Dynorphin–KOR contacts are given in
Table 2 and Table S1. (D) Visual representation of order parameters derived from
NMR relaxation measurements. The width of the cone indicates the flexibility of
G2 (orange), R6 (green), and L12 (red) dynorphin residues in a KOR-bound state.











Fig. 3. Characterization of internal dynorphin dynamics. (A) 15N R2 re-
laxation rate constants (s−1) measured at 600 MHz at 280 K on 15N-(GFLI)-,
15N,13C-(R)-dynorphin in the presence of (red) KOR and (blue) KOR + JDTic.
(B) (gray) Order parameters profile S2/S2max of NH bond vectors derived from
R2 as described in Supporting Information. The order parameters describe
the amplitude of the NH bond fluctuations in the KOR bound state, nor-
malized to L5. (white) Best-fit S2 profiles calculated with the ensemble of
conformers identified by docking and MD simulations.
























increased penetration of water into the receptor cavity, which has
been linked to the activation mechanism upon agonist binding (49).
Mutations of the sodium site in DOR shift nalfurafine, an antago-
nist, to an arrestin-biased ligand, establishing this sodium site as a
key mediator of receptor function (43). The KOR-2 conformation
may hint at the mechanism of dynorphin functional selectivity,
which has been reported as a G protein-biased agonist in phar-
macological in vitro studies (50, 51). The proposed model may be
tested in future studies by mutagenesis of KOR residues that sur-
round dynorphin in the KOR-2 conformation.
The direct quantification of neuropeptide dynamics in an in-
termediate-affinity receptor-bound state yields useful insights for
the design of KOR-targeting antagonists as well as the biology of
peptide-activated receptors. More surprising than the well-defined
α-helical turn between L5 and R9 was the significant motion ob-
served for the N and C termini. Such motion was expected for the
C-terminal part of dynorphin: Indeed, within the message–address
paradigm the highly positively charged C-terminal “address” is
expected to produce favorable but nonspecific electrostatic in-
teractions with the negatively charged extracellular loop 2. In
contrast, this mobility was entirely unexpected for the first four
residues YGGF known to be crucial for the activation of opioid
receptors and form the so-called “message” part of the peptide.
The biology of peptide agonists may also be reflected in flexibly
disordered N and C termini in a bound, but not activating, state. It
is feasible that a combination of attractive and repulsive forces
have been selected for through evolution so that peptide agonists
do not remain bound for excessively long periods, allowing enke-
phalinases to degrade potent bioactive neuropeptides (52). Whereas
GPCRs exist in an array of states with variable ligand affinity, the
observations of dynorphin in complex with KOR indicate that
there are multiple bound states of the peptide that correspond with
various ensembles of activated receptor. We postulate that the
KOR-bound conformation reported here, retaining a significant
degree of freedom, reflects the mechanism of receptor binding and
activation. It would involve, in an initial stage, the association of
helix L5 to R9 into the binding pocket and, in a second stage, the
conversion of the receptor into the active conformation concomi-
tant with structural immobilization of the N-terminal “message”
part of the peptide.
Materials and Methods
Peptide Synthesis. Peptide synthesis was performed using standard solid-
phase synthesis as described in Supporting Information.
KOR Expression, Purification, and Reconstitution in Detergent Micelles. KOR
samples were prepared as previously published and described in Supporting
Information (10).
NMR Experiments. The NMR data were measured at 280 K on a Bruker Avance III
800 MHz for the 15N-(GFLI)–labeled dynorphin and on a Bruker Avance III
600 MHz for the 15N(GFLI)- and 15N-13C(R)–labeled dynorphin. The peptide was
dissolved to 1 mM in a buffer containing 40 mM deuterated MES (Mesd), pH 6.1,
150 mM KCl, 100 μM 2,2 dimethyl-2-silapentane-5-sulfonic acid (DSS), and 10%
D2O for frequency lock. To a 1 mM peptide solution was added KOR recon-
stituted in detergent micelles to a final concentration of 10 μM, a 1:100 ratio of
receptor to ligand. The concentration of DDM was 8 mM and CHS 1.6 mM, re-
spectively, as measured by 1H-NMR. Standard 1D 1H, 1D 13C, 2D [1H, 1H]-TOCSY,
and NOESY experiments were acquired using excitation sculpting for water
suppression (53–55). [15N, 1H]-HSQC, [13C, 1H]-HSQC, [15N, 1H]-IPAP-HSQC, and
CBCANH pulse programs were used to perform the 1H, 15N and 13C-Arg as-
signments of dynorphin in aqueous solvent, with KOR, and with KOR and JDTic
(30, 56–58). The assignments were obtained using the standard reported strategy
for 1H, with 15N and 13C assignments transferred to heteronuclear correlation
experiments based on 1H assignments (28). The 1H, 15N, and 13C assignments of
the free peptide have been deposited in the BMRB (accession no. 25597).
NOESY experiments were acquired at four mixing times: 50, 100, 200, and
500ms to generate build-up curves. 15N relaxation rates, R1 (inversion recovery),
R2 (CPMG), and
1H-15N hetNOEs were measured with established experiments
(59). After data acquisition in the presence of KOR, JDTic was added to a final
concentration of 1 mM and the complete set of NMR experiments was per-
formed again to report on the nonspecific binding of dynorphin.
Structure Determination. Direct comparison of NOE spectra were normalized
in the following manner. NOE volumes in spectra with and without JDTic
were integrated for all mixing times. The integrals were rescaled to take into
account the interactions between groups of equivalent spins. The build-up
curves were fitted to a biexponential analytic function, which permitted
estimation of the cross-relaxation rates. The NOEs in the bound state were
calculated assuming a weighted average of the free and bound states, with
weights equal to populations in both states. Finally, the NOEs were calibrated
with respect to the HN-Hα peaks from the backbone of the peptide. The
initial set of NOEs contained 105 peaks, from which 22 indirect NOEs were
eliminated, characterized by sigmoidal build-up curves, as well as 20 NOEs
with uncertain integrals due to peak overlap. The intraresidual HN-Hα NOEs
were used only for calibration. Hence, in total, 56 NOEs and 4 dihedral angle
restraints (for R6 and R7 dihedral angles) were used for the structure de-
termination (Table 1). Further details of the structure determination pro-
tocol are given in Table S2. The ensemble of 10 best structures have been
deposited in the Protein Data Bank (ID code 2N2F).
15N Relaxation Rates. Relaxation rateswereanalyzedusing the standardequations
described by Farrow (59). In conditions of fast exchange between three states,
namely receptor-bound, nonspecific binding, and the free peptide in solution,
relaxation parameters were measured as a weighted average of their respective
values in each state (60). Owing to the R1 and hetNOE dependence on rotational
diffusion correlation times (Fig. S3), it is academic to establish R1 and hetNOE
should not be significantly affected by the small fraction of bound receptor,
whereas the R2 contribution arising from the bound fraction is proportional to the
NH order parameters in the bound state (Supporting Information).
Molecular Modeling of KOR–Dynorphin Complexes. Details of the molecular
modeling protocols are given in Supporting Information and briefly summarized
here. We started from the 3D structure of KOR-JDTic published in 2012 (9).
Because JDTic induces certain conformational changes by disrupting the salt
bridge involving Gln115, Asp138, and Tyr320, we mutated the known structure
of MOR into KOR (45). Missing side chains were added and optimized using the
SCWRL4 software (61). Out of thousands of possible poses, 10 poses per struc-
ture were retained based on a combination of (i) docking score, (ii) interaction
of the positively charged C terminus with the negatively charged extracellular
loops, and (iii) the competitive binding with JDTic. Each of these poses was then
submitted to a 50-ns MD simulation in explicit water. The equilibrated parts of
the trajectories (the last 20 ns) were used for subsequent analyses.
The energies of intermolecular interaction between dynorphin and KORwere
determined using the MMPBSA method (62). The flexibility of the C terminus on
the nanosecond scale was clearly demonstrated in MD simulations (Fig. S4). In
contrast, the N terminus is fairly rigid in each simulation, with the existence of
distinct starting conformations consistent with reorientations on a slower time
scale. The interconversion between these conformations was still not observed
after a 1-μs MD simulation performed on KOR-2, with NMR restraints required
fixing the central helix. TheMD runs were performed over 50 ns in a periodic box
with explicit solvent, including four water molecules present in crystal structures
of KOR, DOR, and MOR, and with ions neutralizing the charges of the system.
The equilibrated parts of the trajectories have been subject to detailed analysis.
Table 2. Most important contacts between dynorphin and KOR
Dynorphin KOR-1 KOR-2
Interaction energy −22.68 kcal·mol−1 −21.11 kcal·mol−1
Tyr1 Asp138 (3.32) Asp138 (3.32)
Met142 (3.36) Asn141 (3.35)
Val230 (5.42) Asn322 (7.45)
Trp287 (6.48)
Gly2 Asp138 (3.32) Asp138 (3.32)
Tyr139 (3.33)
Gly3 Asp138 (3.32) Asp138 (3.32)
Arg6 Glu209
Arg7 Asp223 (5.35) Asp138 (3.32)
Met226 (5.38)
The receptor contacts are shown with Ballesteros and Weinstein number-
ings for helical residues in parentheses (63). A more detailed list of contacts for
the five major conformations of dynorphin is provided in Table S1. The in-
teraction energies were computed using contacts of dynorphin 1–8 residues.
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